Pomalid4mg – Composition, Uses and Medicine Enquiries
Product Overview
Pomalid4mg is a product listed under the immunomodulatory antineoplastic category. Its active composition is Pomalidomide.
It is associated with relapsed or refractory multiple myeloma in eligible adults. The product modulates immune signaling and interferes with the growth of malignant plasma cells.
Suitability depends on the diagnosis, approved labeling, clinical history and specialist assessment.
This information is provided for education and product identification, not as a recommendation to begin treatment.
Severe birth-defect risk, blood clots and low blood counts require strict pregnancy-prevention procedures and monitoring.
A qualified clinician should confirm whether this exact brand, strength and formulation are appropriate before any prescription or treatment decision.
Composition and Strength
The supplied product information identifies the following composition:
| Active Ingredient | Strength |
|---|---|
| Pomalidomide | Listed product: Pomalid4mg; verify strength against manufacturer packaging |
Product Name: Pomalid4mg
Generic Name: Pomalidomide
Brand Name: Pomalid4mg
Strength: Verify against the original manufacturer-labelled packaging.
Please confirm the exact strength, dosage form, product labeling and manufacturer details against the original product packaging before publishing this product page or proceeding with an enquiry.
Therapeutic Category and Indication
Pomalid4mg belongs to the immunomodulatory antineoplastic category.
Its principal clinical use is associated with relapsed or refractory multiple myeloma in eligible adults.
The active ingredient modulates immune signaling and interferes with the growth of malignant plasma cells.
Treatment eligibility may depend on diagnostic tests, organ function, other medicines and the relevant national prescribing information.
The original spreadsheet category or indication may not accurately represent the brand-specific approval. A qualified pharmacist should check the approved product label before publication.
Severe birth-defect risk, blood clots and low blood counts require strict pregnancy-prevention procedures and monitoring.
Administration Information
Pomalid4mg is supplied as an oral capsule formulation according to the provided product information.
Capsules should be taken whole as directed by the hematologist, following the prescribed treatment cycle.
Patients should follow the exact prescribed route, dose and schedule.
Do not change, share or discontinue this medicine without the treating professional’s advice.
Patients should also review the manufacturer’s patient instructions.
Product Presentation and Availability
The product enquiry can be made using the following details:
- Product Name: Pomalid4mg
- Generic Name: Pomalidomide
- Brand Name: Pomalid4mg
- Therapeutic Category: Anticancer
- Medicine Class: Immunomodulatory Antineoplastic
- Indication: Relapsed or refractory multiple myeloma in eligible adults.
- Dosage Form: Oral Capsules.
- Manufacturer/Marketer: Natco Pharma — attribution requires independent verification.
The master spreadsheet lists Natco Pharma as the manufacturer/marketer. This attribution and the current pack size, dosage form, labeling, batch details and expiry must be independently verified.
No particular packaging, stock or delivery is promised by Medinglobal.
Prescription and Patient Safety
Pomalid4mg is a specialist prescription medicine that requires appropriate clinical supervision.
Severe birth-defect risk, blood clots and low blood counts require strict pregnancy-prevention procedures and monitoring.
Treatment suitability depends on the diagnosis, approved labeling, clinical history and specialist assessment.
Patients should follow the treating hematologist’s instructions and should not independently change, share or discontinue the medicine.
The exact precautions, monitoring requirements and possible adverse effects should be checked against the current approved product information.
Medicine Enquiry Coordination Through Medinglobal
Medinglobal receives enquiries about Pomalid4mg and may coordinate requests for product information with independent, appropriately authorised pharmaceutical providers.
Medinglobal is not the manufacturer, direct seller, dispensing pharmacy or exporter of this product.
Any permitted transaction, prescription check, destination-country assessment, supply terms and supporting documentation are handled by the relevant authorised provider.
An enquiry does not guarantee availability or supply.
How to Submit a Pomalid4mg Enquiry
To help identify the requested product, include the following details when submitting an enquiry:
- Product or brand name: Pomalid4mg.
- Generic name: Pomalidomide.
- Required strength and formulation.
- Required quantity.
- Destination country.
- Valid prescription or institutional documents, when required.
Medinglobal may connect the enquiry with an appropriately authorised independent provider, which must independently confirm legality, product identity and any applicable commercial terms.
Frequently Asked Questions
What is Pomalid4mg used for?
It is associated with relapsed or refractory multiple myeloma in eligible adults, subject to the exact approved label and medical assessment.
What does Pomalid4mg contain?
It contains Pomalidomide. The final composition and strength should be confirmed against the manufacturer’s product packaging.
How is Pomalid4mg administered?
It is supplied as oral capsules. The capsules should be taken whole as directed by the hematologist, following the prescribed treatment cycle.
Does Pomalid4mg require medical supervision?
Yes. It requires specialist supervision, including appropriate pregnancy-prevention procedures and monitoring.
Can I request product information through Medinglobal?
Yes. Medinglobal can coordinate product information enquiries, but supply is neither guaranteed nor directly undertaken by Medinglobal.
Reviews
There are no reviews yet.